论文部分内容阅读
作为国内最大的己内酰胺生产基地,中国石油化工股份有限公司巴陵分公司仅用几千万元的技改资金便完成了国外专家预言需3.5亿元才能完成的“五改七”扩能改造,实现了己内酰胺生产能力由设计年产5万吨到7万吨的跨越,产品的产量、质量、消耗等各项经济技术指标均稳居国内同类装置领先地位,并向新的发展目标“七改十四”(装置年产7万吨扩能改造至年产14万吨)迈进。
As the largest caprolactam production base in China, Baling Branch of China Petroleum & Chemical Corporation has used tens of millions of yuan in technical reform funds to complete the “Five-Reform Seven” expansion and reconstruction that foreign experts predict will cost 350 million yuan to complete. The caprolactam production capacity has achieved a leap from the annual output of 50,000 tons to 70,000 tons. The economic, technical and technical indicators of the products such as output, quality, and consumption have all stayed at the leading position of the same type of domestic equipment, and have achieved seven goals for new development goals. “14” (the annual output of 70,000 tons of equipment to transform into an annual output of 140,000 tons) is moving forward.